COVID-19 still presents uncommon oral manifestations.
In pandemic period, lesions with unusual presentations should be suspected of being associated with COVID-19 infection.
As the pandemic endures, it is crucial for doctors and dentists to be aware of this presentation of mucormycosis associated to COVID 19.
Uncontrolled diabetes, the excessive us of corticosteroids, prolonged neutropenia, hemopoietic malignancies are the most common causes attributed to the rise of mucormycosis in COVID-19.
This paper aims to discuss clinical aspects of mucormycosis. This case series was conducted in two services, comprising six mucormycosis cases during COVID-19 pandemic. About gender, there are 4 (66.7%) males and 2 (33.3%) females with mean age (48.7 ± 9.4) years. All cases presented complaints of pain and swelling in oral cavity and had an aggressive clinical presentation. Five patients had diabetes and one had a nasal non-Hodgkin lymphoma. Histologically, large, branched, hyphae associated with necrotic areas were observed, confirming microscopically such as mucormycosis through PAS and GMS stains. In four cases, treatment consisted in surgical debridement associated with antifungal therapy. All patients were submitted to debridement and received antifungal treatment (amphotericin B). Five patients were followed up without clinical recurrence, but unfortunately one patient died. Diagnosis of mucormycosis should be early because it is related to high mortality. The treatment consists of surgical debridement associated with antifungal therapy.El texto completo de este artículo está disponible en PDF.
Keywords : Coronavirus, Mucormycosis, Infections, Oral diagnosis